Free tool
FAERS Monitor: Opzelura
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215309 or its brand name (Opzelura, Ruxolitinib Phosphate). Reports on generic versions are filed under their own applications.
Reports
15,313
Serious
10,796
71% of reports
Hospitalization
4,226
Death reported
2,698
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,316
- drug ineffective1,422
- product use in unapproved indication859
- death797
- anaemia742
- pyrexia618
- pneumonia589
- thrombocytopenia564
- platelet count decreased536
- pruritus517
- haemoglobin decreased511
- fatigue462
- febrile neutropenia458
- splenomegaly446
- product availability issue434
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 14 |
| 2014 | 22 |
| 2015 | 53 |
| 2016 | 104 |
| 2017 | 209 |
| 2018 | 299 |
| 2019 | 336 |
| 2020 | 530 |
| 2021 | 1,110 |
| 2022 | 1,775 |
| 2023 | 3,230 |
| 2024 | 2,774 |
| 2025 | 2,725 |
| 2026 | 2,121 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,846 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| splenomegalySignal | 446 | 54.3 | 49.5 | 22,404 |
| product availability issueSignal | 434 | 26.7 | 24.3 | 10,505 |
| febrile neutropeniaSignal | 458 | 9.5 | 8.7 | 3,481 |
| thrombocytopeniaSignal | 564 | 7.0 | 6.4 | 2,872 |
| platelet count decreasedSignal | 536 | 6.9 | 6.4 | 2,718 |
| haemoglobin decreasedSignal | 511 | 6.9 | 6.3 | 2,554 |
| anaemiaSignal | 742 | 5.4 | 5.0 | 2,641 |
| product use in unapproved indicationSignal | 859 | 4.8 | 4.5 | 2,580 |
| off label useSignal | 2,316 | 3.6 | 3.5 | 4,612 |
| pneumoniaSignal | 589 | 2.5 | 2.3 | 537 |
| pyrexiaSignal | 618 | 2.5 | 2.3 | 540 |
| pruritus | 517 | 1.8 | 1.7 | 204 |
| drug ineffective | 1,422 | 1.5 | 1.4 | 237 |
| death | 797 | 1.3 | 1.2 | 48 |
| fatigue | 462 | 0.8 | 0.7 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.